| CPC A61K 38/09 (2013.01) [A61K 9/0024 (2013.01); A61K 31/138 (2013.01); A61K 31/4196 (2013.01); A61K 31/566 (2013.01); A61K 47/22 (2013.01); A61K 47/34 (2013.01); A61P 35/00 (2018.01)] | 20 Claims |
|
1. A method of suppressing ovarian function during treatment of hormone receptor-positive breast cancer in a subject comprising
subcutaneously administering to the subject in need thereof about every three months a therapeutically effective amount of a flowable, extended release composition comprising
a) N-methyl-2-pyrrolidone,
b) leuprolide or a pharmaceutically acceptable salt thereof, present in an amount to provide about 26 mg to about 30 mg of a free base equivalent of leuprolide, and
c) a biodegradable polymer comprising co-polymer segments of poly (lactide-co-glycolide) (PLG), wherein a molar ratio of lactide to glycolide monomers is about 75:25, wherein the biodegradable polymer has substantially no titratable carboxylic acid groups, and wherein at least one distal end group of the biodegradable polymer is hydroxyl-terminated, and
wherein upon contact of the flowable, extended release composition with a bodily fluid, the organic solvent dissipates and an in situ solid or semi-solid depot forms.
|